Science Week Conference Presentation

24 June 2022 – Perth, Australia: PharmAust Limited (ASX: PAA & PAAO), a clinical-stage biotechnology company is pleased to provide the enclosed presentation which will be presented tomorrow by Dr Catherine Chan BVSc (Hons I) FANZCVS (Onc) DACVIM (Onc), at the Australian and New Zealand College of Veterinary Scientists (ANZCVS) Annual Scientific Conference, "Science Week".

Dr Chan is a vet oncologist at the Jindalee Veterinary Hospital whose Veterinary Specialist Services division have been a trial centre in PharmAust's B Cell Lymphoma Canine Trials. Dr Chan is also the principal of online veterinary oncology consulting service, The Pet Oncologist.

This announcement is authorised by the Board.

Enquiries:

Dr Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

P +61 (8) 9202 6814
F +61 (8) 9467 6111
W www.pharmaust.com
T @PharmAust

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (code: PAA) and the Frankfurt Stock Exchange (code: ECQ). PAA is a clinical-stage company developing therapeutics for both humans and animals. The company specialises in repurposing marketed drugs lowering the risks and costs of development. These efforts are supported by PAA's subsidiary, Epichem, a highly successful contract medicinal chemistry company that generated $2.2 million in sales of goods & services in FY 2021.

PAA's lead drug candidate is monepantel (MPL), a novel, potent and safe inhibitor of the mTOR pathway – a pathway having key influences in cancer growth and neurodegenerative diseases. MPL has been evaluated in Phase 1 clinical trials in humans and Phase 2 clinical trials in dogs. MPL treatment was well-tolerated in humans, demonstrating preliminary evidence of anticancer activity. MPL demonstrated objective anticancer activity in dogs. PAA is uniquely positioned to commercialise MPL for treatment of human and veterinary cancers as well as neurodegenerative disease as it advances a reformulated version of this drug through Phase 1 and 2 clinical trials.

MPL clinical trial – what's happening?

- Oral anti-cancer tablet administered once daily
- MOA – appears to act as mTOR inhibitor
- Safe in healthy, tumour bearing & lymphoma dogs
- Main side effects at 'high doses' = GI (anorexia, weight loss) + mild hepatopathy (ALP > ALT)
- Phase II clinical trial for dogs with B-cell lymphoma

PharmAust LIMITED



The Pet Oncologist

Phase II clinical trial for B-cell lymphoma

- **Stage I**
  - 15 dogs
  - 3 different doses
  - Duration = 28 days
  - Minimal change in body weight ± 2%
  - **Clinical benefit = 40%** (1 PR, 5 SD, 9 PD)
  - **Post trial analysis on 8 dogs**
    - MPL for 28-days → MPL + prednisolone
    - **MST = 144 days (~5 months)** with 2 dogs still alive
- **Stage 2 – current trial**
  - 4 different doses
  - Duration = 28 days
  - Require ≥ 18 clinical benefit of 46 dogs to meet endpoint

The Pet Oncologist

Dogs eligible for the study

- **Eligibility:**
  - Naïve B-cell lymphoma – cytology or histologic diagnosis (IHC can be pending)
  - Weight ≥ 8 kg
  - Modified Karnofsky performance score 0 or 1 (acceptably functional pet)
  - No other significant diseases
  - Life expectancy >4 weeks
  - No previous medication for the lymphoma
- **Exclusion:**
  - Prednisolone within the last 8 weeks
  - >VCOG grade I adverse effects noted on CBC, Chem + UA
  - Hypercalcaemia
  - <1 year old



The Pet Oncologist

Monitoring

	Day			
	-7 to 0	0	14	28
Physical examination (and response assessment)	x ($ not covered)	x	x	x
Owner log review		x (explanation)	x	x
CBC including smear review (pathologist)	x		x	x
Serum chemistry	x		x	x
Urinalysis including sediment examination	x		x	x
Thoracic radiographs including radiologist interpretation	x			x
Abdominal ultrasound + liver and spleen cytology if abnormal	x			x
LN FNA and cytology (if not already definitive diagnosis of lymphoma)	x			
LN immunophenotyping if not already done*	x			
Start monepantel		x		
Additional blood samples for PK/cytokines		x	x (pre dose)	x (pre dose)
Blood and lymph node samples for PD (select cases only)		x	x (pre dose)	x (pre dose)
Adverse events assessment (VCOG v1.1)			x	x

*If no other exclusion criteria and all inclusion criteria fulfilled and distance is problematic, may start MPL pending

The Pet Oncologist

Study Sites

U-Vet, Melbourne (Stage 1 only)
UVTHS, Sydney (Stage 1 only)
ARH, Sydney
WAVES, Perth
PVS, Perth
ARH, Brisbane
VSS, Brisbane

VSA, Auckland
Heart of Texas, USA

PharmAust LIMITED

The Pet Oncologist